Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Melanoma

 

IL-2 "SELECT" for Advanced Melanoma
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma

Investigator: Kim Margolin, MD;   Conditions: Malignant Melanoma;    Status: Recruiting;   Study ID: NCT01288963

Phase I/II CD8+ NY-ESO-1 (FHCRC 2225)
Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cell Clones and Anti-CTLA4 for Patients With Metastatic Melanoma

Investigator: Aude Chapuis, MD;   Conditions: Melanoma (Skin);    Status: Recruiting;   Study ID: NCT00871481

Tumor-Infiltrating Lymphocytes (TIL) for Metastatic Melanoma (2643)
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma

Investigator: Sylvia M. Lee, MD;   Conditions: Recurrent Melanoma;    Status: Recruiting;   Study ID: NCT01807182

Vemurafenib w/wo Bevacizumab for Stage IV BRAFV600 Mutant Melanoma (7719)
A Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204) with or without Bevacizumab in Patients with Stage IV BrafV600 Mutant Melanoma

Investigator: Kim Margolin, MD;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01495988

Dabrafenib + Trametinib for Melanoma Post Surgery (20130566)
COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection

Investigator: Kim Margolin, MD;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01682083